

## Journal of Pharmacreations



PharmaCreations

ISSN: 2348-6295

Pharmacreations/ Vol 10/ Issue 3/ Jul-Sept 2023

Journal Home Page: [Pharmacreations.com](http://Pharmacreations.com)

Research article

Open Access

### Analytical method development and validation for estimation of rifampicin and isoniazide in bulk and tablet dosage form by high performance liquid chromatography

Senapathi Khyathi Lekha<sup>\*1</sup>, Dr. T.K.V. Kesav Rao<sup>1</sup>, Mr. A.Venkateswara Rao<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Quality Assurance, Pydah College of Pharmacy, Patavala, Andhra University, Kakinada, Andhra Pradesh, India

\*Corresponding Author: Senapathi Khyathi Lekha

Published on: 14.08.2023

#### ABSTRACT

A new, simple and accurate, precise HPLC method was developed for simultaneous determination of Rifampicin and Isoniazide in bulk and in combined pharmaceutical dosage form. The separation of Rifampicin and Isoniazide was achieved within 8 minutes on an Agilent Zorbax (C18) (150mm x 4.6mm, 5 $\mu$ m) column using Methanol: Acetate Buffer pH-3.8 (24:76v/v) as the mobile phase. Detection was carried out using wavelength at 263nm. The method showed adequate sensitivity concerning linearity, accuracy and precision over the range 100-500 $\mu$ g/ml and 30-70 $\mu$ g/ml for Rifampicin and Isoniazide, respectively. Careful validation proved advantages of high sensitivity, accuracy, precision, selectivity, robust and suitability for quality control laboratories. The developed method was robust as the %RSD was within the range and without effecting system suitability parameters. The proposed method is suitable for simultaneous determination of Rifampicin and Isoniazide in bulk and pharmaceutical dosage form.

**Keywords:** Rifampicin and Isoniazide, HPLC, Validation, Precision, Robustness, ICH Guidelines.

#### INTRODUCTION

##### Chromatography <sup>2</sup>

Chromatography is a laboratory technique for the separation of a mixture. The mixture is dissolved in a fluid called the *mobile phase*, which carries it through a structure holding another material called the *stationary phase*. The various constituents of the mixture travel at different speeds, causing them to separate. The separation is based on differential partitioning between the mobile and stationary phases. Subtle differences in a compound's partition coefficient result in differential retention on the stationary phase and thus affect the separation. [1]

Chromatography may be preparative or analytical. The purpose of preparative chromatography is to separate the components of a mixture for later use, and is thus a form of purification. Analytical chromatography is done normally with smaller amounts of material and is for establishing the

presence or measuring the relative proportions of analytes in a mixture. The two are not mutually exclusive. [2]

Chromatography is based on the principle where molecules in mixture applied onto the surface or into the solid, and fluid stationary phase (stable phase) is separating from each other while moving with the aid of a mobile phase. The factors effective on this separation process include molecular characteristics related to adsorption (liquid-solid), partition (liquid-solid), and affinity or differences among their molecular weights [1,2]. Because of these differences, some components of the mixture stay longer in the stationary phase, and they move slowly in the chromatography system, while others pass rapidly into mobile phase, and leave the system faster [3].

Based on this approach three components form the basis of the chromatography technique.

- Stationary phase: This phase is always composed of a "solid" phase or "a layer of a liquid adsorbed on the surface a solid support".

- Mobile phase: This phase is always composed of “liquid” or a “gaseous component.”
- Separated molecules

The type of interaction between stationary phase, mobile phase, and substances contained in the mixture is the basic component effective on separation of molecules from each other. Chromatography methods based on partition are very effective on separation, and identification of small molecules as amino acids, carbohydrates, and fatty acids. However, affinity chromatographies (ie. ion-exchange chromatography) are more effective in the separation of macromolecules as nucleic acids, and proteins. Paper chromatography is used in the separation of proteins, and in studies related to protein synthesis; gas-liquid chromatography is utilized in the separation of alcohol, ester, lipid, and amino groups, and observation of enzymatic interactions, while molecular-sieve chromatography is employed especially for the determination of molecular weights of proteins. Agarose-gel chromatography is used for the purification of RNA, DNA particles, and viruses.

Stationary phase in chromatography, is a solid phase or a liquid phase coated on the surface of a solid phase. Mobile phase flowing over the stationary phase is a gaseous or liquid phase. If mobile phase is liquid it is termed as liquid chromatography (LC), and if it is gas then it is called gas chromatography (GC). Gas chromatography is applied for gases, and mixtures of volatile liquids, and solid material. Liquid chromatography is used especially for thermal unstable, and non-volatile samples.

The purpose of applying chromatography which is used as a method of quantitative analysis apart from its separation, is to achieve a satisfactory separation within a suitable time interval. Various chromatography methods have been developed to that end. Some of them include column chromatography, thin-layer chromatography (TLC), paper chromatography, gas chromatography, ion exchange chromatography, gel permeation chromatography, high-pressure liquid chromatography, and affinity chromatography.

- ✚ Column chromatography
- ✚ Ion-exchange chromatography
- ✚ Gel-permeation (molecular sieve) chromatography
- ✚ Affinity chromatography
- ✚ Paper chromatography
- ✚ Thin-layer chromatography
- ✚ Gas chromatography
- ✚ Dye-ligand chromatography
- ✚ Hydrophobic interaction chromatography
- ✚ Pseudoaffinity chromatography
- ✚ High-pressure liquid chromatography (HPLC)

### High-pressure liquid chromatography (HPLC)

Using this chromatography technique it is possible to perform structural, and functional analysis, and purification of many

molecules within a short time. This technique yields perfect results in the separation, and identification of amino acids, carbohydrates, lipids, nucleic acids, proteins, steroids, and other biologically active molecules. In HPLC, mobile phase passes through columns under 10–400 atmospheric pressure, and with a high (0.1–5 cm/sec) flow rate. In this technique, use of small particles, and application of high pressure on the rate of solvent flow increases separation power, of HPLC and the analysis is completed within a short time.

Essential components of a HPLC device are solvent depot, high- pressure pump, commercially prepared column, detector, and recorder. Duration of separation is controlled. Essential components of a HPLC device are solvent depot, high- pressure pump, commercially prepared column, detector, and recorder. Duration of separation is controlled with the aid of a computerized system, and material is accrued

### Types of HPLC

There are following variants of HPLC, depending upon the phase system (stationary) in the process:

#### Normal Phase HPLC

This method separates analytes on the basis of polarity. NP-HPLC uses polar stationary phase and non-polar mobile phase. Therefore, the stationary phase is usually silica and typical mobile phases are hexane, methylene chloride, chloroform, diethyl ether, and mixtures of these.

Polar samples are thus retained on the polar surface of the column packing longer than less polar materials.

#### Reverse Phase HPLC

The stationary phase is nonpolar (hydrophobic) in nature, while the mobile phase is a polar liquid, such as mixtures of water and methanol or acetonitrile. It works on the principle of hydrophobic interactions hence the more nonpolar the material is, the longer it will be retained.

#### Size-exclusion HPLC


The column is filled with material having precisely controlled pore sizes, and the particles are separated according to their molecular size. Larger molecules are rapidly washed through the column; smaller molecules penetrate inside the porous of the packing particles and elute later.

#### Ion-Exchange HPLC

The stationary phase has an ionically charged surface of opposite charge to the sample ions. This technique is used almost exclusively with ionic or ionizable samples.

The stronger the charge on the sample, the stronger it will be attracted to the ionic surface and thus, the longer it will take to elute. The mobile phase is an aqueous buffer, where both pH and ionic strength are used to control elution time.

## Instrumentation of HPLC



As shown in the schematic diagram in Figure above, HPLC instrumentation includes a pump, injector, column, detector and integrator or acquisition and display system. The heart of the system is the column where separation occurs.

### Solvent Reservoir

Mobile phase contents are contained in a glass reservoir. The mobile phase, or solvent, in HPLC is usually a mixture of polar and non-polar liquid components whose respective concentrations are varied depending on the composition of the sample.

### Pump

A pump aspirates the mobile phase from the solvent reservoir and forces it through the system's column and detector. Depending on a number of factors including column dimensions, particle size of the stationary phase, the flow rate and composition of the mobile phase, operating pressures of up to 42000 kPa (about 6000 psi) can be generated.

### Sample Injector

The injector can be a single injection or an automated injection system. An injector for an HPLC system should provide injection of the liquid sample within the range of 0.1-100 mL of volume with high reproducibility and under high pressure (up to 4000 psi).

### Columns

Columns are usually made of polished stainless steel, are between 50 and 300 mm long and have an internal diameter of between 2 and 5 mm. They are commonly filled with a stationary phase with a particle size of 3–10  $\mu\text{m}$ .

Columns with internal diameters of less than 2 mm are often referred to as microbore columns. Ideally the temperature of the mobile phase and the column should be kept constant during an analysis.

### Detector

The HPLC detector, located at the end of the column detects the analytes as they elute from the chromatographic column. Commonly used detectors are UV-spectroscopy, fluorescence, mass-spectrometric and electrochemical detectors.

### Data Collection Devices

Signals from the detector may be collected on chart recorders or electronic integrators that vary in complexity and in their ability to process, store and reprocess chromatographic data. The computer integrates the response of the detector to each component and places it into a chromatograph that is easy to read and interpret.

## MATERIALS AND METHOD

Rifampicin-Sura labs, Isoniazide-Sura labs, Water and Methanol for HPLC-LICHROSOLV (MERCK), Acetonitrile for HPLC-Merck

### HPLC method development

#### Trails

#### Preparation of standard solution

Accurately weigh and transfer 10 mg of Rifampicin and Isoniazide working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol.

Further pipette 2ml of Rifampicin and 2ml of Isoniazide from the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

#### Procedure

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines.

### Mobile Phase Optimization

Initially the mobile phase tried was Methanol: Water, Acetonitrile and water with varying proportions. Finally, the mobile phase was optimized to Methanol: Acetate Buffer pH-3.8 in proportion 24:76 v/v respectively.

### Optimization of Column

The method was performed with various columns like C18 column, Symmetry and X-Bridge. Agilent Zorbax (C18) (150mm x 4.6mm, 5 $\mu\text{m}$ ) column was found to be ideal as it gave good peak shape and resolution at 1ml/min flow.

**Optimized chromatographic conditions**

Instrument used : Waters HPLC with auto sampler and PDA Detector 996 model.  
 Temperature : 37°C  
 Column : Agilent Zorbax (C18) (150mm x 4.6mm, 5µm) column  
 Mobile phase : Methanol: Acetate Buffer pH-3.8 (24:76v/v)  
 Flow rate : 1ml/min  
 Wavelength : 263nm  
 Injection volume : 10 µl  
 Run time : 8 min

**Method validation****Preparation of mobile phase**


Accurately measured 240 ml (24%) of Methanol and 760 ml of Acetate Buffer (76%) were mixed and degassed in digital ultra sonicator for 15 minutes and then filtered through 0.45 µ filter under vacuum filtration.

**Diluent Preparation**

The Mobile phase was used as the diluent.

**RESULTS AND DISCUSSION****Optimized Chromatogram**

Instrument used : Waters HPLC with auto sampler and PDA Detector 996 model.  
 Temperature : 37°C  
 Column : Agilent Zorbax (C18) (150mm x 4.6mm, 5µm) column  
 Mobile phase : Methanol: Acetate Buffer pH-3.8 (24:76v/v)  
 Flow rate : 1ml/min  
 Wavelength : 263nm  
 Injection volume : 10 µl  
 Run time : 6 min

**Fig 1: Optimized Chromatogram****Table 1: Observation of Optimized Chromatogram**

| S. No. | Peak Name   | Retention Time | Area    | Height | USP Tailing | USP Plate Count | USP Resolution |
|--------|-------------|----------------|---------|--------|-------------|-----------------|----------------|
| 1      | Rifampicine | 1.692          | 1658785 | 385669 | 1.69        | 7586            | 10.85          |
| 2      | Isoniazide  | 3.246          | 425631  | 65245  | 1.58        | 6235            |                |

**Inference**

1. The Retention Time is decreased observed from chromatogram by increasing flow rate.
2. The retention time was Rifampicin and Isoniazide was found to be 1.692 and 3.246 respectively.
3. The tailing is not more than two and plate count observed is more than 2500. Pass all the system suitability parameters.

The peak shapes are good with good resolution and less Retention Time and more theoretical levels, pass the system suitability parameters

**Standard Chromatogram****Table 2: Observation of Standard Chromatogram-1**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Tailing | USP Plate Count | USP Resolution |
|------|------------|----------------------|---------|-------------|-----------------|----------------|
| 1    | Rifampicin | 1.694                | 1659824 | 1.68        | 7595            | 10.89          |
| 2    | Isoniazide | 3.244                | 426521  | 1.59        | 6274            |                |

**Table 3: Observation of standard Chromatogram-2**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing | Resolution |
|------|------------|----------------------|---------|-----------------|-------------|------------|
| 1    | Rifampicin | 1.689                | 1658598 | 7599            | 1.68        | 10.86      |
| 2    | Isoniazide | 3.238                | 426598  | 6254            | 1.57        |            |

**Table 4: Observation of standard Chromatogram-3**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.692                | 1658985 | 7659            | 1.70        |
| 2    | Isoniazide | 3.246                | 425865  | 6359            | 1.59        |

**Table 5: Observation of standard Chromatogram-4**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.688                | 1658579 | 7672            | 1.71        |
| 2    | Isoniazide | 3.265                | 435698  | 6295            | 1.60        |

**Table 6: Observation of standard Chromatogram-5**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.688                | 1659852 | 7695            | 1.69        |
| 2    | Isoniazide | 3.265                | 436598  | 6498            | 1.59        |

**Assay (Sample)****Table 7: Observation of sample Chromatogram-1**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.691                | 1669558 | 7695            | 1.70        |
| 2    | Isoniazide | 3.242                | 436589  | 6359            | 1.61        |

**Table 8: Observation of sample Chromatogram-2**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.694                | 1678598 | 7698            | 1.72        |
| 2    | Isoniazide | 3.240                | 436985  | 6557            | 1.59        |


**Table 9: Observation of sample Chromatogram-3**

| S.No | Peak Name  | Retention Time (min) | Area    | USP Plate Count | USP Tailing |
|------|------------|----------------------|---------|-----------------|-------------|
| 1    | Rifampicin | 1.694                | 1668985 | 7659            | 1.72        |
| 2    | Isoniazide | 3.234                | 436598  | 6347            | 1.61        |

$$\% \text{ASSAY} = \frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

## Linearity


### Chromatographic data for linearity study



**Fig 2: Calibration Curve for Rifampicin**

**Table 10: Linearity Observation of Rifampicin**

| S. No                   | Concentration Level (%) | Concentration $\mu\text{g/ml}$ | Average Peak Area |
|-------------------------|-------------------------|--------------------------------|-------------------|
| 1.                      | I                       | 100                            | 585985            |
| 2.                      | II                      | 200                            | 1182468           |
| 3.                      | III                     | 300                            | 1768785           |
| 4.                      | IV                      | 400                            | 2326852           |
| 5.                      | V                       | 500                            | 2856874           |
| Correlation coefficient |                         |                                | 0.999             |



**Fig 3: Calibration Curve for Isoniazide**

**Table 11: Linearity Observation of Isoniazide**

| S. No. | Concentration Level (%) | Concentration $\mu\text{g/ml}$ | Average Peak Area |
|--------|-------------------------|--------------------------------|-------------------|
| 1      | I                       | 30                             | 268764            |
| 2      | II                      | 40                             | 361958            |

|                         |     |    |        |
|-------------------------|-----|----|--------|
| 3                       | III | 50 | 445631 |
| 4                       | IV  | 60 | 535186 |
| 5                       | V   | 70 | 624698 |
| Correlation coefficient |     |    | 0.999  |

**Table 12: System suitability results Rifampicin**

| Organic phase        |       | System suitability Results |             |                      |
|----------------------|-------|----------------------------|-------------|----------------------|
|                      |       | USP Plate Count            | USP Tailing | Retention Time (min) |
| Less organic phase   | 50:50 | 7269                       | 1.61        | 1.868                |
| Actual organic phase | 55:45 | 7586                       | 1.69        | 1.688                |
| More organic phase   | 60:40 | 7496                       | 1.64        | 1.675                |

**Table 13: System suitability result Isoniazide**

| Organic phase        |       | System suitability Results |             |                      |
|----------------------|-------|----------------------------|-------------|----------------------|
|                      |       | USP Plate Count            | USP Tailing | Retention Time (min) |
| Less organic phase   | 50:50 | 6182                       | 1.54        | 3.621                |
| Actual organic phase | 55:45 | 6235                       | 1.58        | 3.282                |
| More organic phase   | 60:40 | 6322                       | 1.56        | 2.302                |

The tailing factor should be less than 2.0 and the number of theoretical plates (N) should be more than 2000.

## Accuracy

**Table 14: Accuracy Observation of Rifampicin**

| % Concentration<br>(at specification Level) | Average Area | Amount Added<br>(ppm) | Amount Found<br>(ppm) | % Recovery | Mean Recovery |
|---------------------------------------------|--------------|-----------------------|-----------------------|------------|---------------|
| 50%                                         | 879537       | 150                   | 150.048               | 100.032    | 100.112%      |
| 100%                                        | 1743252      | 300                   | 300.521               | 100.172    |               |
| 150%                                        | 2609693      | 450                   | 450.598               | 100.132    |               |

## Isoniazide

**Table 15: Accuracy Observation of Isoniazide**

| % Concentration<br>(at specification Level) | Average Area | Amount Added<br>(ppm) | Amount Found<br>(ppm) | % Recovery | Mean Recovery |
|---------------------------------------------|--------------|-----------------------|-----------------------|------------|---------------|
| 50%                                         | 224271       | 25                    | 25.114                | 100.456%   | 100.16%       |
| 100%                                        | 445748.3     | 50                    | 49.952                | 99.904%    |               |
| 150%                                        | 670006.3     | 75                    | 75.101                | 100.134%   |               |

## CONCLUSION

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Rifampicin and Isoniazide was done by HPLC. The separation was optimized with mobile phase consists of Methanol: acetate buffer (pH-3.8) mixed in the ratio of 24:76%v/v. An Agilent Zorbax (C18) (150mm x 4.6mm, 5µm) column or equivalent chemically bonded to porous silica particles were used as stationary phase. The solutions were chromatographed at a constant flow rate of 1.0 ml/min. The linearity range of Rifampicin and Isoniazide were found to be from 100-500µg/ml, 30-70µg/ml respectively. Linear regression coefficient was not more than 0.999, 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies

from 98-102% of Rifampicin and Isoniazide. LOD and LOQ were found to be within limits.

The results obtained on the validation parameters met ICH and USP requirements. It inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

## ACKNOWLEDGEMENT

The Authors are thankful to the Management and Principal, Department of Pharmacy, Pydah College of Pharmacy , Kakinada, Andhra Pradesh for extending support to carry out the research work. Finally, the authors express their gratitude to the Sura Labs, Dilsukhnagar, Hyderabad, for providing research equipment and facilities.

## REFERENCES

1. Berry RI, Nash AR. Pharmaceutical process validation, Analytical method validation, Marcel Dekker Inc. New York. 1993;57:411-28.
2. Moffat AC, Osselton MD, Widdop B. Clarke's analysis of drugs and poisons. Vol. 2004. London: Pharmaceutical press; 1601-1602. p. 1109-10.
3. Florey K. Analysis profile of drugs substances. New York: Academic press; 2005. p. 406-35.
4. Sethi PD. HPLC: quantitative analysis pharmaceutical formulations, CBS publishers and distributors. New Delhi, India; 2001. p. 3-137.
5. Michael E, Scharzt IS, Krull. Analytical method development and validation; 2004. p. 25-46.
6. Snyder R, Kirkland J, Glajch L. Practical HPLC method development. 2nd ed. A Wiley international publication; 1997, P.235,266-268,351-353.653-600.686-695.
7. Basic education in analytical chemistry. Anal Sci. 2001;17(1).
8. Method validation guidelines international Conference on harmonization; GENEVA; 1996.
9. Sharma BK. Instrumental methods of chemical analysis, Introduction to analytical chemistry. 23rd ed. Goel publishing house meerut; 2004. p. 12-23.
10. Willard HH, Merritt LL, Dean JA, Settle FA. Instrumental methods of analysis. 7th ed, CBS publishers and distributors. New Delhi; 1986. p. 518-21, 580-610.
11. Adamovics J. Chromatographic analysis of pharmaceutical. 2nd ed. New York: Marcel Dekker Inc. p. 74, 5-15.
12. Chatwal G, Anand SK. Instrumental methods of chemical analysis. 5th ed. New Delhi: Himalaya publishing house; 2002. p. 1.1-8, 2.566-70.
13. Skoog DA, Holler J, Nieman TA. Principle of instrumental analysis. 5th ed, Saunders college publishing; 1998. p. 778-87.
14. Skoog, Holler, Nieman. Principals of instrumental analysis. 5th ed, Harcourt publishers international company; 2001. p. 543-54.
15. Kemp W. Organic spectroscopy. New York: Palgrave; 2005. p. 7-10, 328-30.
16. Arora PN, Malhan PK. Biostatistics, Himalaya publishers house, India, P.113,139-140,154.
17. Doserge, Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. 8th ed. Lippincott Company; 1982. p. 183-97.
18. Available from: <https://www.drugbank.ca/drugs/DB00921>.
19. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine>.
20. Available from: <https://en.wikipedia.org/wiki/Buprenorphine#:~:text=Buprenorphine%2C%20sold%20under%20the%20brand,patch%2C%20or%20as%20an%20implant>. Wikipedia.